Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Tumor Biology
Erschienen in: Tumor Biology 4/2014

01.04.2014 | Research Article

The volume and duration of wound drainage are independent prognostic factors for breast cancer

verfasst von: Yan Zhang, Hua Gao, Wei Gao

Erschienen in: Tumor Biology | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Drain insertion is routinely done after breast cancer surgery. However, the prognostic value of suction drains in breast cancer is still unknown. This study aimed to reveal the prognostic value of drain insertion in breast cancer. A total of 296 female breast cancer patients undergoing surgery were retrospectively recruited. The correlation of drainage volume as well as drain duration with clinicopathological parameters and prognosis was assessed statistically. We found that breast cancer patients with a drainage volume of >240 ml had a better overall survival time. Breast cancer patients with more than 5 days postoperative drain duration would have better survival time. In addition, both the volume and duration of wound drainage are independent prognostic factors in multivariate analysis. Therefore, the volume of drainage as well as drain duration is a potential novel prognostic marker for breast cancer.
Literatur
1.
2.
Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol. 2003;21:3357–65.PubMedCrossRef
3.
Kuroi K, Shimozuma K, Taguchi T, Imai H, Yamashiro H, Ohsumi S, et al. Pathophysiology of seroma in breast cancer. Breast Cancer. 2005;12:288–93.PubMedCrossRef
4.
Woodworth PA, McBoyle MF, Helmer SD, Beamer RL. Seroma formation after breast cancer surgery: incidence and predicting factors. Am Surg. 2000;66:444–50. discussion 450–441.PubMed
5.
Sakkary MA. The value of mastectomy flap fixation in reducing fluid drainage and seroma formation in breast cancer patients. World J Surg Oncol. 2012;10:8.PubMedCentralPubMedCrossRef
6.
Lumachi F, Brandes AA, Burelli P, Basso SM, Iacobone M, Ermani M. Seroma prevention following axillary dissection in patients with breast cancer by using ultrasound scissors: a prospective clinical study. Eur J Surg Oncol. 2004;30:526–30.PubMedCrossRef
7.
Shamley DR, Barker K, Simonite V, Beardshaw A. Delayed versus immediate exercises following surgery for breast cancer: a systematic review. Breast Cancer Res Treat. 2005;90:263–71.PubMedCrossRef
8.
Kontos M, Petrou A, Prassas E, Tsigris C, Roy P, Trafalis D, et al. Pressure dressing in breast surgery: is this the solution for seroma formation? J BUON. 2008;13:65–7.PubMed
9.
Ruggiero R, Procaccini E, Piazza P, Docimo G, Iovino F, Antoniol G, et al. Effectiveness of fibrin glue in conjunction with collagen patches to reduce seroma formation after axillary lymphadenectomy for breast cancer. Am J Surg. 2008;196:170–4.PubMedCrossRef
10.
He XD, Guo ZH, Tian JH, Yang KH, Xie XD. Whether drainage should be used after surgery for breast cancer? A systematic review of randomized controlled trials. Med Oncol. 2011;28 Suppl 1:S22–30.PubMedCrossRef
11.
Talbot ML, Magarey CJ. Reduced use of drains following axillary lymphadenectomy for breast cancer. ANZ J Surg. 2002;72:488–90.PubMedCrossRef
12.
Moss JP. Historical and current perspectives on surgical drainage. Surg Gynecol Obstet. 1981;152:517–27.PubMed
13.
Agrawal A, Ayantunde AA, Cheung KL. Concepts of seroma formation and prevention in breast cancer surgery. ANZ J Surg. 2006;76:1088–95.PubMedCrossRef
14.
Saratzis A, Soumian S, Willetts R, Rastall S, Stonelake PS. Use of multiple drains after mastectomy is associated with more patient discomfort and longer postoperative stay. Clin Breast Cancer. 2009;9:243–6.PubMedCrossRef
15.
Barton A, Blitz M, Callahan D, Yakimets W, Adams D, Dabbs K. Early removal of postmastectomy drains is not beneficial: results from a halted randomized controlled trial. Am J Surg. 2006;191:652–6.PubMedCrossRef
16.
Gupta R, Pate K, Varshney S, Goddard J, Royle GT. A comparison of 5-day and 8-day drainage following mastectomy and axillary clearance. Eur J Surg Oncol. 2001;27:26–30.PubMedCrossRef
17.
Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol. 2002;20:3628–36.PubMedCrossRef
18.
Iovino F, Auriemma PP, Ferraraccio F, Antoniol G, Barbarisi A. Preventing seroma formation after axillary dissection for breast cancer: a randomized clinical trial. Am J Surg. 2012;203:708–14.PubMedCrossRef
19.
Lin YP, Yin WJ, Yan TT, Zhou LH, Di GH, Wu J, et al. Risk factors for postoperative seromas in Chinese breast cancer patients. Chin Med J (Engl). 2011;124:1300–4.
20.
21.
Li X, Kong X, Chen X, Zhang N, Jiang L, Ma T, et al. LAPTM4B allele *2 is associated with breast cancer susceptibility and prognosis. PLoS One. 2012;7:e44916.PubMedCentralPubMedCrossRef
22.
Hormbrey E, Han C, Roberts A, McGrouther DA, Harris AL. The relationship of human wound vascular endothelial growth factor (VEGF) after breast cancer surgery to circulating VEGF and angiogenesis. Clin Cancer Res. 2003;9:4332–9.PubMed
23.
Wu FP, Hoekman K, Meijer S, Cuesta MA. VEGF and endostatin levels in wound fluid and plasma after breast surgery. Angiogenesis. 2003;6:255–7.PubMedCrossRef
24.
Tagliabue E, Agresti R, Carcangiu ML, Ghirelli C, Morelli D, Campiglio M, et al. Role of HER2 in wound-induced breast carcinoma proliferation. Lancet. 2003;362:527–33.PubMedCrossRef
25.
Fisher B, Gunduz N, Coyle J, Rudock C, Saffer E. Presence of a growth-stimulating factor in serum following primary tumor removal in mice. Cancer Res. 1989;49:1996–2001.PubMed
26.
Hofer SO, Shrayer D, Reichner JS, Hoekstra HJ, Wanebo HJ. Wound-induced tumor progression: a probable role in recurrence after tumor resection. Arch Surg. 1998;133:383–9.PubMedCrossRef
27.
Barwell J, Campbell L, Watkins RM, Teasdale C. How long should suction drains stay in after breast surgery with axillary dissection? Ann R Coll Surg Engl. 1997;79:435–7.PubMedCentralPubMed
28.
Horgan K, Benson EA, Miller A, Robertson A. Early discharge with drain in situ following axillary lymphadenectomy for breast cancer. Breast. 2000;9:90–2.PubMedCrossRef
Metadaten
Titel
The volume and duration of wound drainage are independent prognostic factors for breast cancer
verfasst von
Yan Zhang
Hua Gao
Wei Gao
Publikationsdatum
01.04.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 4/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1470-z

Weitere Artikel der Ausgabe 4/2014

Tumor Biology 4/2014 Zur Ausgabe

Research Article

Association between a functional insertion/deletion polymorphism in IL1A gene and risk of papillary thyroid carcinoma

Research Article

Hexokinase 2 overexpression promotes the proliferation and survival of laryngeal squamous cell carcinoma

Research Article

Gly82Ser polymorphism of the receptor for advanced glycation end-product (RAGE) potential high risk in patients with colorectal cancer

Research Article

Polymorphisms of Toll-like receptor 9 are associated with nasopharyngeal carcinoma susceptibility

Research Article

p21 overexpression sensitizes osteosarcoma U2OS cells to cisplatin via evoking caspase-3 and Bax/Bcl-2 cascade

Research Article

Clinical significance of S100A2 expression in gastric cancer

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise